Imunon, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IMNN in the last 30 days.
See all $IMNN insider activity →China SXT Pharmaceuticals (SXTC) rose 7% after terminating an additional purchase right tied to its recent offering. Imunon (IMNN) surged 18% following a deal to sell ThermoDox rights, potentially receiving $16.5M in milestone payments. HeartSciences (HSCS) gained 13% after filing a proxy statement for a proposed merger with Fortitude Mining, creating a digital asset mining platform.
IMUNON (IMNN) sold ThermoDox rights to VoxelDox for 4.76% equity, up to $16.5M in milestones, and 3.5%-6% royalties. Deal awaits VoxelDox's $2.5M financing. IMUNON focuses on ovarian cancer trial IMNN-001.
Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON’s Commitment to Its Core S
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning IMNN (Imunon, Inc.). Coverage has been balanced: 1 bullish, 4 neutral, and 1 bearish.
Recent IMNN coverage spans corporate actions, financial news and earnings.
Positive catalyst from the asset sale and potential equity stake.
The deal provides near‑term cash and upside from the equity stake, but dilutes existing shareholders.
The deal removes a legacy asset but provides cash and upside via equity, likely causing short‑term price pressure as investors reassess pipeline focus.
Company will present at Maxim Growth Summit and ThinkEquity Conference.
The capital raise adds cash but also dilutes existing shareholders; short‑term price may see modest upside as financing is confirmed.
AlphAI scores every news story that mentions IMNN with an AI model for sentiment and relevance, and aggregates insider trades from Imunon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
China SXT Pharmaceuticals (SXTC) rose 7% after terminating an additional purchase right tied to its recent offering. Imunon (IMNN) surged 18% following a deal to sell ThermoDox rights, potentially receiving $16.5M in milestone payments. HeartSciences (HSCS) gained 13% after filing a proxy statement for a proposed merger with Fortitude Mining, creating a digital asset mining platform.
2 min readIMUNON (IMNN) sold ThermoDox rights to VoxelDox for 4.76% equity, up to $16.5M in milestones, and 3.5%-6% royalties. Deal awaits VoxelDox's $2.5M financing. IMUNON focuses on ovarian cancer trial IMNN-001.
2 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON’s Commitment to Its Core S
2 min readIMUNON, Inc. (Nasdaq: IMNN) announced its CEO will participate in the Maxim Growth Summit and ThinkEquity Conference in October 2026. The company is a clinical-stage biotech firm developing DNA-mediated immunotherapies, with a focus on advanced ovarian cancer treatment and a COVID-19 booster vaccine.
2 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and t
2 min readImunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.
7 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory
2 min readIMUNON (IMNN) reported Q2 2026 results and an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer. The company said enrollment is progressing faster than expected and expects completion in 1H 2029. It cited Phase 2 OVATION 2 median OS of 45.1 vs 30.4 months and MRD/ctDNA clearance improvements. Net loss was $2.8M.
4 min readImunon, Inc. (IMNN) said its OVATION 3 Phase III enrollment is ahead of plan and that IMNN-001 has strong safety and efficacy data, according to an Aug. 11, 2026 Q2 2026 audio transcript. The company reported stable financials and a $10 million financing to extend its runway through year-end 2026.
1 min readImunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enroll
6 min read
